Sub-Tenon Sustained Controllable Delivery of Dexamethasone for Treating Severe Acute Experimental Uveitis

REFERENCES

• Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705–717. doi:10.5301/ejo.5000278.
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:10.1080/09273948.2016.1196713.
   PubMed Web of Science ®Google Scholar
• Chen EJ, Bin Ismail MA, Mi H, et al. Ocular autoimmune systemic inflammatory infectious study (OASIS) – report 1: epidemiology and classification. Ocul Immunol Inflamm. 2018;26(5):732–746. doi:10.1080/09273948.2016.1249376.
   PubMed Web of Science ®Google Scholar
• Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology. 2014;121(1):365–376. doi:10.1016/j.ophtha.2013.08.029.
   PubMed Web of Science ®Google Scholar
• Lee K, Bajwa A, Freitas-Neto CA, Metzinger JL, Wentworth BA, Foster CS. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opin Pharmacother. 2014;15(15):2141–2154. doi:10.1517/14656566.2014.948417.
   PubMed Web of Science ®Google Scholar
• Rodriguez Villanueva J, Rodriguez Villanueva L, Guzman Navarro M. Pharmaceutical technology can turn a traditional drug, dexamethasone into a first-line ocular medicine. A global perspective and future trends. Int J Pharm. 2017;516(1–2):342–351. doi:10.1016/j.ijpharm.2016.11.053.
   PubMed Web of Science ®Google Scholar
• Kang-Mieler JJ, Dosmar E, Liu W, Mieler WF. Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications. Expert Opin Drug Deliv. 2017;14(5):611–620. doi:10.1080/17425247.2016.1227785.
   PubMed Web of Science ®Google Scholar
• Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57(14):2010–2032. doi:10.1016/j.addr.2005.09.004.
   PubMed Web of Science ®Google Scholar
• Kramer M, Ehrlich R, Snir M, et al. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet’s disease. Am J Ophthalmol. 2004;138(4):666–667. doi:10.1016/j.ajo.2004.04.064.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24(5):587–611. doi:10.1016/j.preteyeres.2005.01.004.
   PubMed Web of Science ®Google Scholar
• Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178–183. doi:10.1097/ICU.0b013e328338679a.
   PubMed Web of Science ®Google Scholar
• Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006;141(4):629–637. doi:10.1016/j.ajo.2005.11.050.
   PubMed Web of Science ®Google Scholar
• Berarducci A, Sian IS, Ling R. Inadvertent dexamethasone implant injection into the lens body management. Eur J Ophthalmol. 2014;24(4):620–622. doi:10.5301/ejo.5000436.
   PubMed Web of Science ®Google Scholar
• Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014;121(1):67–71. doi:10.1016/j.ophtha.2013.06.033.
   PubMed Web of Science ®Google Scholar
• El-Ghrably IA, Saad A, Dinah C. A novel technique for repositioning of a migrated ILUVIEN((R)) (fluocinolone acetonide) implant into the anterior chamber. Ophthalmol Ther. 2015;4(2):129–133. doi:10.1007/s40123-015-0035-1.
   PubMed Web of Science ®Google Scholar
• Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014;121(11):2275–2286. doi:10.1016/j.ophtha.2014.05.021.
   PubMed Web of Science ®Google Scholar
• Leder HA, Jabs DA, Galor A, et al. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(3):441–448.e442. doi:10.1016/j.ajo.2011.02.009.
   PubMed Web of Science ®Google Scholar
• Chan JE, Pridgen TA, Csaky KG. Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon’s implant in the rat. Exp Eye Res. 2010;90(4):501–506. doi:10.1016/j.exer.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008;14:150–160.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim ES, Geroski DH, et al. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. Invest Ophthalmol Vis Sci. 2008;49(10):4506–4514. doi:10.1167/iovs.08-1989.
   PubMed Web of Science ®Google Scholar
• Huang X, Peng M, Yang Y, et al. Dexamethasone distribution characteristic following controllable continuous sub-tenon drug delivery in rabbit. Drug Deliv. 2017;24(1):818–824. doi:10.1080/10717544.2017.1324531.
   PubMed Web of Science ®Google Scholar
• Huang X, Liu S, Yang Y, et al. Controllable continuous sub-tenon drug delivery of dexamethasone disodium phosphate to ocular posterior segment in rabbit. Drug Deliv. 2017;24(1):452–458. doi:10.1080/10717544.2016.1264498.
   PubMed Web of Science ®Google Scholar
• Cheng CK, Berger AS, Pearson PA, et al. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36(2):442–453.
   PubMed Web of Science ®Google Scholar
• Madow B, Galor A, Feuer WJ, et al. Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. Am J Ophthalmol. 2011;152(2):170–176.e171. doi:10.1016/j.ajo.2011.01.058.
   PubMed Web of Science ®Google Scholar
• Papangkorn K, Prendergast E, Higuchi JW, et al. Noninvasive ocular drug delivery system of dexamethasone sodium phosphate in the treatment of experimental uveitis rabbit. J Ocul Pharmacol Ther. 2017;33(10):753–762. doi:10.1089/jop.2017.0053.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–471.
   PubMed Web of Science ®Google Scholar
• Ghosn CR, Li Y, Orilla WC, et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(6):2917–2923. doi:10.1167/iovs.10-5939.
   PubMed Web of Science ®Google Scholar
• Ayyildiz O, Durukan AH, Ozgurtas T, Gunal A. A comparison of intravitreal bevacizumab and steroid activity in an experimental uveitis model. Curr Eye Res. 2015;40(12):1261–1268. doi:10.3109/02713683.2014.995310.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Yang CS, Wang XC, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105(1):46–56.
   PubMed Web of Science ®Google Scholar
• Barry RJ, Tallouzi MO, Bucknall N, et al. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database Syst Rev. 2018;12:Cd012577.
   PubMedGoogle Scholar
• Waite D, Wang Y, Jones D, et al. Posterior drug delivery via periocular route: challenges and opportunities. Ther Deliv. 2017;8(8):685–699. doi:10.4155/tde-2017-0097.
   PubMed Web of Science ®Google Scholar
• Luo L, Yang J, Oh Y, et al. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. J Control Release. 2019;296:68–80. doi:10.1016/j.jconrel.2019.01.018.
   PubMed Web of Science ®Google Scholar
• Wong CW, Czarny B, Metselaar JM, et al. Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Sci Rep. 2018;8(1):6604. doi:10.1038/s41598-018-24545-2.
   PubMedGoogle Scholar
• Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48(5):2230–2237. doi:10.1167/iovs.06-0954.
   PubMed Web of Science ®Google Scholar
• Kumar DA, Agarwal A, Karnathi S, Patadiya R. Anterior segment optical coherence tomography for imaging the sub-tenon space. Ophthalmic Res. 2013;50(4):231–234. doi:10.1159/000354381.
   PubMedGoogle Scholar
• Paganelli F, Cardillo JA, Melo LA Jr., et al. A single intraoperative sub-tenon’s capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery. Invest Ophthalmol Vis Sci. 2009;50(7):3041–3047. doi:10.1167/iovs.08-2920.
   PubMed Web of Science ®Google Scholar
• Duan Y, Yang Y, Huang X, Lin D. Preliminary study of a controllable device for subtenon drug infusion in a rabbit model. Acta Ophthalmol. 2017;95(6):595–601. doi:10.1111/aos.13448.
   PubMed Web of Science ®Google Scholar
• Sun S, Li J, Li X, et al. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-epsilon-caprolactone (PCL). Acta Biomater. 2016;37:143–154. doi:10.1016/j.actbio.2016.04.014.
   PubMed Web of Science ®Google Scholar